

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	11
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	24
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	41
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	44
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	47
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Lao PDR (East and South East Asia)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	NK	NK	NK
Year of IDU prevalence estimate			
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	NK	NK	NK
Year of HIV prevalence among IDU estimate			
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	3 608 504 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	NK	NK	NK
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	NK	NK	NK

1. Needle and syringe programs (NSPs)**NSP 1: Availability of NSPs**

Are NSPs available?	No
Comments	
Most recent year of documentation	2006
Reference	<p>Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.</p> <p>UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).</p> <p>Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).</p> <p>World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.</p>
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

NSP 2: Number of NSP sites

Data reported	0 sites		
Year of reported data	2006		
Reference	<p>Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.</p> <p>UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).</p> <p>Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).</p> <p>World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	0	0	0

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	0 clients		
Year of reported data	2006		
Reference	<p>Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.</p> <p>UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).</p> <p>Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).</p> <p>World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	0	0	0

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	0 occasions of service		
Year of reported data	2006		
Reference	<p>Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.</p> <p>UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).</p> <p>Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).</p> <p>World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	0	0	0

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	0 syringes and needles distributed		
Year of reported data	2006		
Reference	<p>Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.</p> <p>UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).</p> <p>Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).</p> <p>World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	0	0	0

NSP: All documents reviewed

Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).

Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.

UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).

World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	No
Comments	
Most recent year of documentation	2009
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).
When was agonist OST first available?	
Reference	

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	No
Comments	
Most recent year of documentation	2009
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).
When was MMT first available?	
Reference	

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	no
Comments	
Most recent year of documentation	2009
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).
When was BMT first available?	
Reference	

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	No
Comments	
Most recent year of documentation	2009
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	0	0	0

OST 8: Number of sites providing MMT

Data reported	MMT not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 9: Number of sites providing BMT

Data reported	BMT not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 11: Number of all clients in any OST at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 12: Number of all clients in MMT at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 13: Number of all clients in BMT at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	0	0	0

OST 16: Number of IDUs in MMT at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	0	0	0

OST 17: Number of IDUs in BMT at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	0	0	0

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	0	0	0

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	0	0	0

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	0	0	0

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	0	0	0

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported	OST not available		
Year of reported data	2009		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 717 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High
	0	0	0

OST: All documents reviewed

Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.

HIV/AIDS Asia Regional Program (HAARP) (2006). Program design document - Final.

UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).

World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	Opiate detoxification usually involving tincture of opium and herbal medicine administered over a 15 - 42 day period at an inpatient detoxification centre Methadone also used for detoxification		
Year of reported data	2006		
Reference	Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 2.3: Number of all clients in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 4.2: Number of IDUs in peer-based support groups

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK		NK

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	Unspecified		
Number of sites - data reported	Drug treatment available but number of sites not known		
Year of reported data	2005		
Reference	ACCORD (2005). Towards a drug free ASEAN and China 2015: Assessing ACCORD progress 2000-2005. UNODC Regional Centre for East Asia and the Pacific and Association of Southeast Asian Nations.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 302 229 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	Drug treatment available but number of IDUs in treatment not known		
Year of reported data	2005		
Reference	ACCORD (2005). Towards a drug free ASEAN and China 2015: Assessing ACCORD progress 2000-2005. UNODC Regional Centre for East Asia and the Pacific and Association of Southeast Asian Nations.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 302 229 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	3500 people received treatment for opium abuse in 2004-2005 [No information on whether this refers to compulsory and/or voluntary treatment, nor on type of treatment provided, nor on whether this refers to a 2 or 1 year period]		
Year of reported data	2005		
Reference	ACCORD (2005). Towards a drug free ASEAN and China 2015: Assessing ACCORD progress 2000-2005. UNODC Regional Centre for East Asia and the Pacific and Association of Southeast Asian Nations.		
Adjustments	Assumed 12 month period		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	3500 (?V/C)		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 302 229 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 6 - Drug treatment in prisons**ODT 6.1: Number of prison drug treatment sites**

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported	7 compulsory drug rehabilitation centres, involving drug detoxification		
Year of reported data	2006		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft). Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	7		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported	Compulsory drug treatment present but number of IDUs not available		
Year of reported data	2006		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft). Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 399 915 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported	833 drug users in compulsory drug rehabilitation including 49 women and 784 men		
Year of reported data	2008		
Reference	UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).		
Adjustments	Assumed single point in time		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	833		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 608 504 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	

ODT: All documents reviewed

ASEAN and China Cooperative Operations in Response to Dangerous Drugs (ACCORD) (2005). Towards a drug free ASEAN and China 2015: Assessing ACCORD progress 2000-2005. UNODC Regional Centre for East Asia and the Pacific and Association of Southeast Asian Nations.

Devaney, M., Reid, G. and Baldwin, S. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Papers. J. Stokes. Canberra, Australian National Council on Drugs: 215.

UN Regional Task Force on Injecting Drug Use and HIV/AIDS for Asia and the Pacific (2009). Lao PDR country advocacy brief - Injecting drug use and HIV/AIDS (Draft).

UNODC Regional Centre for East Asia and the Pacific (2006). HIV/AIDS and custodial settings in South East Asia - An exploratory review into the issues of HIV/AIDS and custodial settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam. Thailand.

World Health Organization Regional Office for the Western Pacific (2007). The harm reduction SIDA project for the greater Mekong subregion (HR3) first project advisory committee meeting. Phnom Penh, Cambodia, World Health Organization Regional Office for the Western Pacific.

4. HIV testing and counselling (T&C)**T&C 1: Availability of HIV T&C**

Is T&C available?	
Most recent year of data	
Reference	

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High
	NK	NK	NK

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	
Reference	
Data reported for both male and female IDUs	
Adjustments	
Final/Adjusted data	
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

T&C: All documents reviewed

No references recorded

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	3 sites		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 608 504 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
HIV among IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level HIV among IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	NK	NK	NK

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	Number of IDUs on ART not known		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	3 608 504 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
HIV among IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Estimate of country level HIV among IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	NK	NK	NK

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

Asian Harm Reduction Network (AHRN) (2004). *Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).*

Country coordination committee - Laos (2008). *Scaling up HIV and AIDS prevention, care and treatment in Lao PDR.* Vientiane: 85.

Mesquita, F., D. Jacka, et al. (2008). "Accelerating harm reduction interventions to confront the HIV epidemic in the Western Pacific and Asia: the role of WHO (WPRO)." *Harm Reduction Journal* 5(1): 26.

National Committee for the Control of AIDS (2005). *Country Report: Lao People's Democratic Republic:* 17.

WHO, UNAIDS., et al. (2009). *Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009.* Geneva, WHO.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	
Comments	
Year	
Reference	

Condoms 2: Number of sites distributing condoms to IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High
	NK	NK	NK

Condoms 4: Number of condoms distributed to IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

Country coordination committee - Laos (2008). Scaling up HIV and AIDS prevention, care and treatment in Lao PDR. Vientiane: 85.

Family Health International (2007). Asia regional program final report. Arlington VA: 65.